The EPIC cardiac substudy showed that Exjade removed iron from the heart in beta-thalassemia patients, based on a statistically significant improvement in T2* magnetic resonance imaging, a validated ...
Switzerland based Novartis (NVS) recently announced the approval of Exjade (deferasirox) by the European Commission. Exjade has been approved for the treatment of chronic iron overload requiring ...
These patients are detected with non-transfusion-dependent thalassemia (NTDTY) syndrome along with a liver iron concentration of at least 5 mg of iron per gram dry weight and a serum ferritin ...
To earn CME related to this news article, click here. January 28, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of the risk for effects on pacing or ...
May 23, 2007 -- Renal failure and cytopenias have been reported in patients receiving deferasirox oral suspension tablets ( Exjade; Novartis Pharmaceuticals Corp), according to the US Food and Drug ...
EAST HANOVER, N.J., January 23, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Exjade ® (deferasirox) for the treatment of chronic iron ...
The FDA has notified healthcare professional of an Early Communication regarding an ongoing review of safety issues with Exjade (deferasirox tablets for oral suspension, from Novartis). New safety ...
13 March 2007Two and a half year efficacy and safety data in a wide range of underlying diseases in patients as young as two years confirm initial findings.Additional results from ESCALATOR trial show ...
New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply ...
Please provide your email address to receive an email when new articles are posted on . The FDA has expanded the approved use of deferasirox to treat patients aged at least 10 years with chronic iron ...
Exjade indication for inherited blood disorder expanded Deferasirox (Exjade, Novartis) has been approved to reduce iron overload in thalassemia patients aged 10 years and older, who do not require ...
Switzerland based Novartis ( NVS) recently announced the approval of Exjade (deferasirox) by the European Commission. Exjade has been approved for the treatment of chronic iron overload requiring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results